BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


King Pharmaceuticals, Inc. - Sterile Products Operations 

870 Parkdale Road

Rochester  Michigan  48307  U.S.A.
Phone: 248-651-9081 Fax:


King Pharmaceuticals, Inc. is a vertically integrated pharmaceutical company that manufactures, markets and sells primarily branded prescription pharmaceutical products for a variety of pharmaceutical and biotechnology companies.

With 90 employees, in January 1994 King Pharmaceuticals opened the doors of its 450,000 square foot facility in Bristol, Tennessee, as a contract manufacturer of prescription medicines for other leading pharmaceutical companies. Soon after, the company adopted its present strategy of selectively acquiring branded prescription pharmaceutical products being divested. Gaining recognition throughout the pharmaceutical industry as a trustworthy and innovative leader, the company has established a strong record of growth through strategic purchases of well-known pharmaceuticals, effective marketing of our products, and product life-cycle management.

Today, King employs approximately 1,900 people involved in all disciplines of a major pharmaceutical enterprise, including scientific development, regulatory, medical affairs, quality assurance/quality control, product development, manufacturing, and sales and marketing. It operates five manufacturing facilities that produce a broad array of dosage forms including tablets, capsules, liquids, suspensions, solutions, suppositories, creams, ointments, injectibles, and other drug products for human and animal health. The Company markets a variety of branded prescription products primarily over four therapeutic areas, including cardiovascular products, women's health products/endocrinology products, anti-infective products and critical care products.

In March 1998, King Pharmaceuticals established Parkedale Pharmaceuticals (now known as King Pharmaceuticals, Sterile Products Operations). The emphasis at this facility is on sterile manufacturing, and it employs approximately 450 associates. The Rochester, Michigan site manufactures sterile products for King, as well as clinical and commercial drugs for numerous pharmaceutical and biotechnology companies worldwide. Some of the products currently manufactured at this facility are Remicade (injection) for treatment of rheumatoid arthritis and Crohn's disease, Benadryl (injection) for treatment of hay fever and allergies, and Nutropin (injection) a hormone used for children who do not make enough of this growth hormone on their own. This facility is also currently working together with Novavax on manufacturing HPV-16 VLP vaccines being evaluated by the National Cancer Institute in clinical trials. The vaccines are designed to prevent and/or treat HPV-16 infection and associated cervical cancer.

Key Management:

  • John M. Gregory, Chairman

    Last Updated: 06-07-02

     Key Statistics

    Ownership: Public

    Web Site: King Pharmaceuticals, Inc. - Sterile Products Operations
    Employees: 1,900 Company wide (450 - Sterile Products Operations-Rochester, Michigan)
    Symbol: KG

  • Industry

     Company News
    King Pharmaceuticals, Inc. - Sterile Products Operations (KG) Offers New Dosage Strengths of AVINZA(R) to Provide More Treatment Options for People with Chronic Pain 2/5/2009 9:52:29 AM
    King Pharmaceuticals, Inc. - Sterile Products Operations (KG) To Present At JPMorgan Healthcare Conference 1/5/2007 12:01:21 PM
    King Pharmaceuticals, Inc. - Sterile Products Operations (KG) Reports Arbitration Results Regarding Dispute With Elan Corporation PLC (ELN) 12/18/2006 1:37:31 PM
    King Pharmaceuticals, Inc. - Sterile Products Operations (KG) Release: New Patient Support Program Offers Savings On Glumetza(TM) Therapy For Type 2 Diabetes 11/21/2006 11:21:05 AM
    King Pharmaceuticals®, Inc. Announces Appointment Of Philip A. Incarnati To Board Of Directors 11/7/2006 11:37:05 AM
    King Pharmaceuticals®, Inc. Announces Date For Release Of Third-Quarter 2006 Financial Results 11/3/2006 11:04:08 AM
    New Drug Shown To Lower Risk Of Diabetes 9/18/2006 9:50:08 AM
    King Pharmaceuticals, Inc. - Sterile Products Operations (KG) To Webcast Live Conference Call10/19/2005 5:13:15 PM
    Palatin Technologies (PTN) And King Pharmaceuticals, Inc. - Sterile Products Operations (KG) Announce Formation Of Scientific Advisory Board For PT-14110/19/2005 5:13:14 PM
    King Pharmaceuticals, Inc. - Sterile Products Operations (KG) To Webcast Live Conference Call10/19/2005 5:13:10 PM